Agilon Health, Inc. (AGL) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Agilon Health operates a Medicare-centric, globally capitated line of business through partnerships with physician groups. As of March 31, 2026, the Company provided care to approximately 426,300 Medicare Advantage (MA) members and participates in CMS ACO Models. The Company is a Large Accelerated Filer. Notably, the Company effected a 1-for-25 reverse stock split on March 30, 2026, to regain compliance with NYSE listing standards; all per-share data in this filing has been retroactively adjusted.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenues | $1,420.5 million | $1,532.8 million |
| Net Income (Attributable to Common Shares) | $48.9 million | $12.1 million |
| Diluted EPS | $2.94 | $0.73 |
| Medical Margin (Non-GAAP) | $148.9 million | $128.0 million |
| Adjusted EBITDA (Non-GAAP) | $53.8 million | $20.6 million |
| Cash and Cash Equivalents | $139.9 million | $173.7 million |
| Restricted Cash | $71.6 million | $0 |
| Marketable Securities | $91.4 million | $111.4 million |
| Total Debt (Current + Long-term) | $30.0 million | $35.0 million |
| Operating Cash Flow | $23.7 million | ($32.0 million) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 7% to $1.42 billion, driven by a 13% decline in average MA membership due to strategic market exits and disciplined contracting focused on profitability.
- Profitability Improvement: Despite lower revenue, Net Income increased 304% to $48.9 million. This was driven by a 16% increase in Medical Margin ($148.9M vs $128.0M) and a 18% reduction in General and Administrative expenses.
- Discontinued Operations: The Company recorded $19.0 million in income from discontinued operations (Hawaii divestiture adjustments), compared to $14.0 million in the prior year.
- Cash Flow Turnaround: Operating cash flow swung from a $32.0 million outflow in Q1 2025 to a $23.7 million inflow in Q1 2026, attributed to improved medical margins and timing of payor settlements.
- Debt Restructuring: The Company amended its Credit Facility in February 2026, extending the maturity to 2028 and requiring cash collateralization for letters of credit, resulting in $71.6 million of restricted cash.
Outlook, Risks, and Management Commentary
- Management Transition: Tim O'Rourke was appointed as Chief Executive Officer and President, with an expected commencement date of May 7, 2026.
- Strategic Focus: Management emphasized a "disciplined approach to contracting" and exiting unprofitable markets to improve margins, even at the cost of total membership volume.
- Legal Proceedings: The Company is defending multiple securities class action lawsuits and shareholder derivative actions alleging misstatements regarding financial guidance and medical margins. Discovery is ongoing, and the Company cannot estimate potential losses.
- Liquidity: The Company maintains $211.6 million in total cash (including restricted) and $91.4 million in marketable securities. It believes these resources, plus available borrowing capacity, are sufficient for the next 12 months.
- Risk Factors: Key risks include reliance on a limited number of payors, potential delisting if share price criteria are not met (though currently compliant post-split), and the impact of CMS risk adjustment settlements.
Investor Verification Checklist
- Membership Trends: Verify the sustainability of the 13% membership decline and the impact of new payor contracts on future revenue growth.
- Medical Margin Quality: Assess the drivers of the improved medical margin (e.g., favorable claims development vs. permanent cost reductions) and the risk of future claim volatility.
- Legal Exposure: Monitor the status of the consolidated securities litigation and derivative actions for potential settlement costs or reputational damage.
- Debt Covenants: Review the new Credit Facility covenants, specifically the requirement to maintain $50 million in total cash and the conditions for dividend payments.
- Reverse Stock Split Impact: Confirm the trading liquidity and price stability of the stock following the 1-for-25 reverse split.